NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's Copaxone reduced the risk of patients developing multiple sclerosis after they showed an initial sign of the central nervous system ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results